Almirall Aims To File Once Daily Aclidinium Bromide For COPD In Europe In Early 2010

Almirall, S.A. (ALM.MC) today announced its intention to file a Marketing Authorization Application (MAA) with the European Medicines Agency (EMEA) for its once-daily long acting muscarinic antagonist Eklira® (aclidinium bromide) in early 2010, for the maintenance bronchodilator treatment and symptom control of COPD.